The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients
The DOI matches its Crossref record; 44 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid (GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS (Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [102]
In the citing paper
“When patients cut their GC dose in half (from 20-30 mg to 10-15 mg HC daily), mean body weight decreased by 7.1 kg after 6-12 months (209).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [209]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodCholesterol determination in high-density lipoproteins separated by three different methods.
Lopes-Virella, M. F., Stone, P., Ellis, S., & Colwell, J. A. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.5.882 · Cited by 1,841 · cited 5×
“This study was carried out in Eu- First Published Online August 8, 2006 Abbreviations: AE, Adverse event; AS, ACTH-sufficient (patients); BMI, body mass index; BP, blood pressure; CA, cortisone acetate; CI, confidence interval; DHEA, dehydroepiandrostenedione; DHEAS, DHEA sulfate; DM, diabetes mellitus; DX, dexamethas…”
MethodInfluentialGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“This could explain some of the metabolic features and increased cardiovascular mortality associated with severe GHD (9).”
BackgroundThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“ease, with no safe lower dose threshold (38, 39).”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 8×
“Recently, a reduction in GC dose has been advocated because physiological cortisol production has been shown to be lower than previously thought (10).”
BackgroundInfluentialCanalis, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3441 · Cited by 463
Brabant, G., von zur Mühlen, A., Wüster, C., Ranke, M. B., Kratzsch, J., Kiess, W., Ketelslegers, J.-M., Wilhelmsen, L., Hulthén, L., Saller, B., et al. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071871 · Cited by 360 · cited 1×
“In subsequent years, a chemiluminescence immunoassay was used (Nichols Advantages system) (20).”
MethodSelf-citation
Cited by
Items 101–200 of 346
Ekman, B., Fitts, D., Marelli, C., Murray, R. D., Quinkler, M., & Zelissen, P. M. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-40 · Cited by 31
“Conventional glucocorticoid replacement therapy has also been associated with reduced bone mineral density [17], depending on the dose [18], as well as with unfavourable metabolic effects [19] and an increased risk of cardiovascular disease [20].”
BackgroundOptimal glucocorticoid replacement in adrenal insufficiency
Øksnes, M., Ross, R. J. M., & Løvås, K. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.009 · Cited by 35
Improved salivary cortisol rhythm with dual-release hydrocortisone
Ceccato, F., Selmin, E., Sabbadin, C., Costa, M. D., Antonelli, G., Plebani, M., Barbot, M., Betterle, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0257 · Cited by 32
Radiotherapy as a tool for the treatment of Cushing’s disease
Castinetti, F., Brue, T. C., & Ragnarsson, Ó. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0092 · Cited by 33
Staufenbiel, S. M., Andela, C. D., Manenschijn, L., Pereira, A. M., van Rossum, E. F. C., & Biermasz, N. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4328 · Cited by 29
“A higher daily hydrocortisone dose has been previously linked to a more adverse cardiometabolic risk profile, characterized by a higher BMI (20).”
BackgroundChantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Bergthorsdottir, R., Gudbjörnsdottir, S., Svensson, A.-M., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0657 · Cited by 30
Self-citationFactors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
Dineen, R., Stewart, P. M., & Sherlock, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13837 · Cited by 30
Borresen, S. W., Thorgrimsen, T. B., Jensen, B., Hilsted, L., Bartels, E. M., Feldt‐Rasmussen, U., & Locht, H. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa011 · Cited by 31
Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy
Johannsson, G., & Ragnarsson, Ó. (2014) · Frontiers of hormone research · doi:10.1159/000360556 · Cited by 36
Self-citationTritos, N. A., Hamrahian, A. H., King, D., Greenspan, S. L., Cook, D. M., Jönsson, P. J., Wajnrajch, M. P., Koltowska-Häggstrom, M., & Biller, B. M. K. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0070 · Cited by 24
Ross, I. L., Bergthorsdottir, R., Levitt, N., Dave, J. A., Schatz, D., Marais, D., & Johannsson, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090768 · Cited by 29
“There may be a negative association between dose exposure and bone mineral density [37] and lower doses may be associated with better health related quality of life [6,38,39].”
BackgroundSelf-citationHealth-related quality of life in primary and secondary adrenal insufficiency
Aulinas, A., & Webb, S. M. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.963559 · Cited by 32
“An unhealthy metabolic profile has been observed in SAI treated with HC replacement doses above 20 mg/day (higher BMI, higher triglycerides and low-density lipoprotein cholesterol levels) [13].”
BackgroundBehan, L.-A., Carmody, D., Rogers, B., Hannon, M. J., Davenport, C., Tormey, W., Smith, D., Thompson, C. J., Stanton, A., & Agha, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1187 · Cited by 28
Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient’s Perspective
Claessen, K. M. J. A., Andela, C. D., Biermasz, N. R., & Pereira, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701365 · Cited by 33
Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review
Caetano, C. M., & Malchoff, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.897211 · Cited by 29
“In a 3- month trial, decreasing HC from 30 mg/d to 15 mg/d in 13 patients was well tolerated, but there was no change in a variety of cardiometabolic end points including blood pressure, weight, plasma and urinary electrolytes, and serum glucose or HbA1C (28).”
BackgroundCosta, U. M. M., Oliveira, C. R. P., Salvatori, R., Barreto-Filho, J. A. S., Campos, V. C., Oliveira, F. T., Rocha, Í. E. S., Oliveira, J. L. M., Silva, W. A., & Aguiar-Oliveira, M. H. (2016) · Endocrine Connections · doi:10.1530/ec-15-0118 · Cited by 30
Johannsson, G., Lennernäs, H., Marelli, C., Rockich, K. T., & Skrtic, S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1212 · Cited by 29
Self-citationBehan, L., Rogers, B., Hannon, M. J., O’Kelly, P., Tormey, W., Smith, D., Thompson, C. J., & Agha, A. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04074.x · Cited by 27
Negri, M., Pivonello, C., Simeoli, C., Gennaro, G. D., Venneri, M. A., Sciarra, F., Ferrigno, R., de Angelis, C., Sbardella, E., Martino, M. C. D., et al. (2020) · Neuroendocrinology · doi:10.1159/000512685 · Cited by 27
Sheehan syndrome: a current approach to a dormant disease
Karaca, Z., & Keleştimur, F. (2025) · Pituitary · doi:10.1007/s11102-024-01481-1 · Cited by 32
The chronic syndromes after previous treatment of pituitary tumours
Romijn, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.84 · Cited by 28
Ebrahimi, F., Kutz, A., Wagner, U., Illigens, B. M. W., Siepmann, T., Schüetz, P., Christ‐Crain, M., Müeller, B., & Christ, E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa517 · Cited by 28
Sun, X., Feng, M., Lü, L., Zhao, Z., Bao, X., Deng, K., Yao, Y., Zhu, H., & Wang, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.600323 · Cited by 30
“Although GC replacement therapy has been associated with increased TG, TC, and LDL concentrations in patients with hypopituitarism (34), a recent study by Choi et al.”
ResultSheehan syndrome: Cardiovascular and metabolic comorbidities
Laway, B. A., & Baba, M. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1086731 · Cited by 30
“In addition to GH deficiency, excess GC replacement worsens metabolic profile of hypopituitary subjects which increases their risk for CV diseases (43).”
BackgroundNofal, A. A., Bancos, I., Benkhadra, K., Ospina, N. S., Javed, A., Kapoor, E., Muthusamy, K., Brito, J. P., Turcu, A. F., Wang, Z., et al. (2016) · Endocrine Practice · doi:10.4158/ep161428.or · Cited by 29
Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL
Buning, J. W., Dimova, L. G., Perton, F. G., Tietge, U. J. F., van Beek, A. P., & Dullaart, R. P. F. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12770 · Cited by 26
Ceccato, F., Torchio, M., Tizianel, I., Falb, M. P., Barbot, M., Sabbadin, C., Betterle, C., & Scaroni, C. M. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01889-1 · Cited by 25
“The observed reduction in total and LDL cholesterol in the longitudinal evaluation can reflect both an increased use of lipid lowering medication in the aging patients and the reduction of GC treatment, as observed in hypopituitary patients [34].”
Ramadan fasting in patients with adrenal insufficiency
Chihaoui, M., Chaker, F., Yazidi, M., Grira, W., Amor, Z. B., Rejeb, O., & Slimane, H. (2016) · Endocrine · doi:10.1007/s12020-016-1186-0 · Cited by 26
“Indeed, its long-term use can lead to metabolic adverse events [24].”
BackgroundBuning, J. W., Brummelman, P., Koerts, J., Dullaart, R. P. F., van den Berg, G., van der Klauw, M. M., Tucha, O. M., Wolffenbuttel, B. H. R., & van Beek, A. P. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.02.001 · Cited by 26
Olsson, D. S., Bryngelsson, I., & Ragnarsson, Ó. (2016) · Pituitary · doi:10.1007/s11102-016-0764-8 · Cited by 24
“This includes constantly improving imaging techniques, establishment of growth hormone as a part of the replacement therapy regime, and adjustment of the glucocorticoid replacement therapy towards a near-physiological pattern [10–13].”
MethodGlycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?
Graziadio, C., Hasenmajer, V., Venneri, M. A., Gianfrilli, D., Isidori, A. M., & Sbardella, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00434 · Cited by 24
“Considering a progressive worsening of the metabolic status in hypopituitary patients receiving doses greater than 20 and greater than 30 mg/day, the mean daily dose of hydrocortisone prescribed should be lower than 30mg (40).”
BackgroundBehan, L.-A., Kelleher, G., Hannon, M. J., Brady, J. J., Rogers, B., Tormey, W., Smith, D., Thompson, C. J., McKenna, M. J., & Agha, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0596 · Cited by 23
Cardio‐metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling
Henley, D., & Lightman, S. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12422 · Cited by 25
Surgical remission of Cushing's syndrome reduces cardiovascular risk
Terzolo, M., Allasino, B., Pia, A., Peraga, G., Daffara, F., Laino, F., Ardito, A., Termine, A., Paccotti, P., Berchialla, P., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0555 · Cited by 23
Dai, W., Lund, H., Chen, Y., Zhang, J., Osinski, K. I., Zellner-Jones, S., Kreuziger, L. B., López, J. A., Benjamin, I. J., Silverstein, R. L., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.002 · Cited by 23
Long-Acting Hydrocortisone for Glucocorticoid Replacement Therapy
Johannsson, G., Filipsson, H., Bergthorsdottir, R., Lennernäs, H., & Skrtic, S. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110621 · Cited by 23
“However, most estimates of dose equivalency among GCs are based on the anti-inflammatory effects and, thus, these estimates cannot reflect all metabolic aspects of GC replacement therapy.We evaluated the metabolic outcomes of different GC replacement therapies by comparing a large group of adult adrenocorticotropic ho…”
MethodSelf-citationLennernäs, H., Skrtic, S., & Johannsson, G. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.6.749 · Cited by 25
“Recently, it has been observed that there is a link between unphysiological and overly high dose of glucocortiocoid therapy and poor cardiovascular risk profile, with abdominal obesity and an atherogenic lipid profile [36] .”
BackgroundSelf-citationSaving lives of patients with adrenal insufficiency: a pan‐ European initiative?
Quinkler, M., Hahner, S., Johannsson, G., & Stewart, P. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12378 · Cited by 22
Self-citationWatanabe, T., Ozawa, A., Ishii, S., Tomaru, T., Shibusawa, N., Saito, T., Yamada, E., Horiguchi, K., Nakajima, Y., Matsumoto, S., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej16-0387 · Cited by 22
Flynn, B. P., Birnie, M. T., Kershaw, Y. M., Pauža, A. G., Kim, S., Baek, S., Rogers, M. F., Paterson, A. R., Stavreva, D. A., Murphy, D., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009737 · Cited by 22
“Surprisingly however, despite clinicians’ best attempts to provide an ‘optimal’ replacement regime, many patients suffer from a range of metabolic and cognitive side effects [19,62].”
BackgroundHe, X., & Barkan, A. L. (2020) · Pituitary · doi:10.1007/s11102-020-01031-5 · Cited by 25
Barbosa, E. J. L., Koranyi, J., Nyström, H. F., Bengtsson, B., Boguszewski, C. L., & Johannsson, G. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0973 · Cited by 26
Self-citationImproving outcomes in patients with adrenal insufficiency: a review of current and future treatments
Johannsson, G., Skrtic, S., Lennernäs, H., Quinkler, M., & Stewart, P. M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.925865 · Cited by 21
Self-citationThe management of glucocorticoid deficiency: Current and future perspectives
Dineen, R., Martin‐Grace, J., Thompson, C. J., & Sherlock, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.006 · Cited by 21
Quagliarini, F., Makris, K., Friano, M. E., & Uhlenhaut, N. H. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad048 · Cited by 22
Group 4: Replacement therapy for adrenal insufficiency
Castinetti, F., Guignat, L., Bouvattier, C. M., Samara‐Boustani, D., & Reznik, Y. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.007 · Cited by 20
Ebrahimi, F., Widmer, A., Wagner, U., Müeller, B., Schüetz, P., Christ‐Crain, M., & Kutz, A. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0469 · Cited by 21
Yuen, K. C. J., Kołtowska‐Häggström, M., Cook, D. M., Fox, J. L., Jönsson, P., Geffner, M. E., & Abs, R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3631 · Cited by 20
Petersen, K. S., Rushworth, R. L., Clifton, P. M., & Torpy, D. J. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0058-6 · Cited by 23
Recent Advances in Hydrocortisone Replacement Treatment
Mallappa, A., & Debono, M. (2015) · Endocrine development · doi:10.1159/000439329 · Cited by 22
Metabolic syndrome and its components in adult hypopituitary patients
Abe, S. Y., dos Santos, K. S., Barbosa, B. F. B., Biondo, C., Takito, D., Hayashi, S. K., Amarilla, V. G. V., Ulbrich, A. Z., & Boguszewski, C. L. (2020) · Pituitary · doi:10.1007/s11102-020-01048-w · Cited by 22
Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study
Dineen, R., Martin‐Grace, J., Ahmed, K. M. S., Frizelle, I. M., Gunness, A., Garrahy, A., Hannon, A. M., O’Reilly, M., Smith, D., McDermott, J., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0642 · Cited by 20
Sherlock, M., Behan, L., Hannon, M. J., Alonso, A. A., Thompson, C. J., Murray, R. D., Crabtree, N. J., Hughes, B. A., Arlt, W., Agha, A., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0490 · Cited by 19
An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory
Castinetti, F., Sahnoun, M., Albarel, F., Morange, I., Philippon, M., Conte‐Devolx, B., & Brue, T. C. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.11.004 · Cited by 21
Tritos, N. A., Hamrahian, A. H., King, D., Greenspan, S. L., Cook, D. M., Jönsson, P. J., Koltowska‐Häggstrom, M., & Biller, B. M. K. (2013) · Clinical Endocrinology · doi:10.1111/cen.12132 · Cited by 18
Recombinant Human Growth Hormone: Rationale for Use in the Treatment of HIV-Associated Lipodystrophy
Benedini, S., Terruzzi, I., Lazzarin, A., & Luzi, L. (2008) · BioDrugs · doi:10.2165/00063030-200822020-00003 · Cited by 18
“In fact, a recent paper by Filipsson and associates[106] Additionally, GH administration in the absence of true GHD showed the impact of different glucocorticoid regimens in patients did not show metabolic benefits in a study conducted in obese with hypopituitarism (KIMS population) after 1 year of GH treatpatients wi…”
Daily adjustment of glucocorticoids by patients with adrenal insufficiency
Schöfl, C., Mayr, B. M., Maison, N., Beuschlein, F., Meyer, G., Badenhoop, K. W. J., Kienitz, T., & Quinkler, M. O. (2019) · Clinical Endocrinology · doi:10.1111/cen.14004 · Cited by 19
Demarchis, L., Chiloiro, S., Giampietro, A., Marinis, L. D., Bianchi, A., Fleseriu, M., & Pontecorvi, A. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09957-6 · Cited by 19
Hayashi, R., Tamada, D., Murata, M., Kitamura, T., Mukai, K., Maeda, N., Otsuki, M., & Shimomura, I. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00420 · Cited by 17
Soluble adhesion molecules levels in patients with Cushing’s syndrome before and after cure
Ermetici, F., Malavazos, A. E., Corbetta, S., Eller-Vainicher, C., Cannavò, S., Corsi, M. M., & Ambrosi, B. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346381 · Cited by 16
Garmes, H. M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09872-8 · Cited by 16
Schlechte, J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2410 · Cited by 15
“(29) that GH-deficient adults with ACTH deficiency treated with a daily hydrocortisone equivalent greater than 25 mg had higher total cholesterol, triglycerides, waist circumference, and hemoglobin A1C levels than GH-deficient subjects taking no hydrocortisone suggest another cause for the increased mortality.”
BackgroundWolf, P. S., Mayr, J., Beiglböck, H., Fellinger, P., Winhofer, Y., Poglitsch, M., Gessl, A., Kautzky‐Willer, A., Luger, A., & Krebs, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0086 · Cited by 16
Bitencourt, M. R., Batista, R. L., Biscotto, I. P., & Carvalho, L. R. S. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000493 · Cited by 16
“Ekstrand and cols. showed worse body composition and metabolic profile outcomes in patients with CAI who changed from cortisone acetate to HCeq (53), which was reinforced by Filipsson and cols. (54).”
BackgroundInfluentialBioletto, F., Sibilla, M., Gasco, V., Ghigo, E., & Grottoli, S. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02356-9 · Cited by 14
“This is in line with findings in other contexts [36, 37, 41], in which higher glucocorticoid replacement doses were associated with an adverse cardiometabolic profile, and with a consequent increase in morbidity and mortality.”
ResultEspiard, S., McQueen, J., Sherlock, M., Ragnarsson, Ó., Bergthorsdottir, R., Burman, P., Dahlqvist, P. M., Ekman, B., Engström, B. E., Skrtic, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa862 · Cited by 15
“It has been postulated that this could be induced by current modes of GC replacement and depends on various factors including excess weight, central adiposity, impaired glucose tolerance, dyslipidemia, and immunosuppression (7-11).”
BackgroundSelf-citationDineen, R., Martin‐Grace, J., Ahmed, K. M. S., TAYLOR, A. E. R., Shaheen, F., Schiffer, L., Gilligan, L. C., Lavery, G. G., Frizelle, I. M., Gunness, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad370 · Cited by 14
Guidelines for diagnosis and treatment of adrenal insufficiency in adults
Novoa, P. D. M., Vela, E. T., García, N. P., Rodríguez, M. M., Guerras, I. S., Santamaría, M. D. L. Á. M. D. S., & Aulinas, A. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/s2173-5093(14)70069-8 · Cited by 16
Ceccato, F., Barbot, M., Lizzul, L., Selmin, E., Saller, A., Albiger, N. M. E., Betterle, C., Boscaro, M., & Scaroni, C. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13490 · Cited by 15
Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review
Mongioì, L. M., Condorelli, R. A., Barbagallo, F., Vignera, S. L., & Calogero, A. E. (2020) · Endocrine · doi:10.1007/s12020-020-02187-7 · Cited by 15
Baroni, M. G., Giorgino, F., PEZZINO, V., Scaroni, C. M., & Avogaro, A. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.001 · Cited by 15
The Glucocorticoid Taper: A Primer for the Clinicians
Priya, G., Laway, B. A., Ayyagari, M., Gupta, M., Bhat, G. H. K., & Dutta, D. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_410_23 · Cited by 14
“[1,14,17,18] Therefore, there is an urgent need for steroid stewardship to minimise risk and optimise the benefit‑to‑risk ratio.”
BackgroundLessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY
Luger, A., Feldt‐Rasmussen, U., Abs, R., Gaillard, R. C., Buchfelder, M., Trainer, P. J., & Brue, T. C. (2011) · Hormone Research in Paediatrics · doi:10.1159/000329156 · Cited by 13
Current and future treatment options for adrenal insufficiency
Arshad, M. F., & Debono, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000637 · Cited by 13
“The foremost reason for higher than average mortality in AI is related to cardiovascular disease with an increased prevalence of risk factors [17] and cardiovascular events such as heart attacks and strokes [18].”
BackgroundNyström, H. F., Saveanu, A., Barbosa, E. J. L., Barlier, A., Enjalbert, A., Glad, C. A. M., Palming, J., Johannsson, G., & Brue, T. C. (2010) · Pituitary · doi:10.1007/s11102-010-0278-8 · Cited by 13
“4% of the cohort had IPI, which is in agreement with other studies [1, 2].”
BackgroundResultSelf-citationKhan, M. I., Habra, M. A., McCutcheon, I. E., Nogueras-Gonzdlez, G. M., Devin, J. K., Busaidy, N. L., Levine, N. B., Lindstrom, W. A., Kagan, D., Jiménez, C., et al. (2011) · Endocrine Practice · doi:10.4158/ep11013.or · Cited by 13
Plasma renin levels are associated with cardiac function in primary adrenal insufficiency
Wolf, P. S., Beiglböck, H., Fellinger, P., Pfleger, L., Aschauer, S., Gessl, A., Marculescu, R., Trattnig, S., Kautzky‐Willer, A., Luger, A., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01974-1 · Cited by 14
Wang, X., Magkos, F., Patterson, B. W., Reeds, D. N., Kampelman, J., & Mittendorfer, B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0180 · Cited by 13
Dullaart, R. P. F., Schols, J. L., van der Steege, G., Zelissen, P. M. J., Sluiter, W. J., & van Beek, A. P. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03196.x · Cited by 14
The Pituitary Gland and Age-Dependent Regulation of Body Composition
van Beek, A. P., Wolffenbuttel, B. H. R., Runge, E., Trainer, P. J., Jönsson, P., & Kołtowska‐Häggström, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2506 · Cited by 16
“The mechanisms may be only partially related to being overweight and obese and could also be the result of excess glucocorticoid replacement therapy (39, 48) and GH deficiency (50).”
BackgroundAn Overview of Cardiovascular Risk in Pituitary Disorders
Ntali, G., Markussis, V., & Chrisoulidou, A. (2024) · Medicina · doi:10.3390/medicina60081241 · Cited by 13
“HC equivalent doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile [200].”
BackgroundPatients with adrenal insufficiency have cardiovascular features associated with hypovolemia
Espósito, D., Bobbio, E., Fraia, R. D., Mone, P., Accardo, G., Bellis, A. D., Iorio, S., Esposito, K., Marfella, R., Johannsson, G., et al. (2020) · Endocrine · doi:10.1007/s12020-020-02458-3 · Cited by 12
Self-citationGuarnotta, V., Amodei, R., & Giordano, C. S. D. S. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.003 · Cited by 14
Ectopic lipid metabolism in anterior pituitary dysfunction
Baumgartner, C., Krššák, M., Vila, G., Krebs, M., & Wolf, P. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1075776 · Cited by 12
“On the contrary, in patients suffering from adrenal insufficiency even a small oversupply of daily glucocorticoid substitution therapy was associated with an adverse cardiometabolic risk profile, characterized by an increase in visceral adipose tissue, higher fasting glucose values and hypertension (47).”
BackgroundBlacha, A. K., Kropp, P. A., Rahvar, A., Flitsch, J., van de Loo, I., & Harbeck, B. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02731-y · Cited by 12
“1 3 increased cardiovascular risk [4, 5], premature mortality [6, 7], and impaired cognitive functioning [8–10].”
Gasco, V., Giannelli, J., Campioni, L., Arvat, E., Ghigo, E., Grottoli, S., Maccario, M., & Giordano, R. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01940-1 · Cited by 12
“These abnormalities could be secondary to both supra-physiological GC doses used in the past (> 20 mg/day hydrocortisone, HC) [4], or to a more physiological GC doses used nowadays (≤ 20 mg/day HC), but unable to replicate the endogenous cortisol circadian rhythm [5].”
BackgroundChen, A. X., & Burt, M. G. (2022) · Clinical Endocrinology · doi:10.1111/cen.14850 · Cited by 11
“However, there is a hydrocortisone dose‐ dependent increase in LDL cholesterol and triglycerides in patients with secondary adrenal insufficiency before growth hormone replacement.(71) Patients with adrenal insufficiency prescribed pred-”
BackgroundGuignat, L., Proust-Lemoine, E., Reznik, Y., & Zénaty, D. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.009 · Cited by 11
“dditionally with an increase in waist circumference [2].”
BackgroundInfluentialBoesen, V. B., Borresen, S. W., Christoffersen, T., Klose, M., Watt, T., & Feldt‐Rasmussen, U. (2020) · Endocrine · doi:10.1007/s12020-020-02507-x · Cited by 11
Höybye, C., Burman, P., Feldt‐Rasmussen, U., Hey‐Hadavi, J., Aydin, F., Camacho‐Hübner, C., & Mattsson, A. F. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0576 · Cited by 11
Self-citationRagnar Agnarsson, H., Johannsson, G., & Ragnarsson, O. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3851 · Cited by 10
“Adverse metabolic profile (26), lower BMD (8, 27), and impaired health-related quality of life (28, 29) have all been associated with high GC replacement doses.”
BackgroundSelf-citationWild, C. M., Stieg, M. R., Stalla, G. K., Auer, M. K., & Athanasoulia-Kaspar, A. P. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02582-7 · Cited by 10
Long-term effects of treatment of pituitary adenomas
Pereira, A. M. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00024-1 · Cited by 11
Outcomes of the short Synacthen test: what is the role of the 60 min sample in clinical practice?
Dineen, R., Mohamed, A. H. H., Gunness, A., Rakovac, A., Cullen, E., Barnwell, N., Neary, C., Behan, L., Boran, G. P., Gibney, J., et al. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136669 · Cited by 10
Hypopituitarism and Cardiovascular Risk
Kraljević, I., Solak, M., Mandić, A., Kozamernik, K. M., Raičević, M., Divanović, A., Kovačević, Z., & Muzurović, E. M. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251332398 · Cited by 10
“However, when the dose was reduced to the equivalent of HC 20 mg/day or less, which was demonstrated in a large Scandinavian study ( n = 2,424 patients with hypopituitarism), metabolic endpoints did not differ from patients not requiring GCs. 84 Patients with secondary AI on GC replacement had larger waist circumferen…”
InfluentialHindmarsh, P. C., & Honour, J. W. (2020) · International Journal of Endocrinology · doi:10.1155/2020/2470956 · Cited by 9
“Recentreviews of causes of mortality in CAH in children and adrenal insufficiency in adults [7–9] point to cortisol deficiency as the primary cause in many instances.”
Pituitary disease mortality: is it fiction?
Erfurth, E. M., Siesjö, P., & Björk‐Eriksson, T. (2013) · Pituitary · doi:10.1007/s11102-013-0469-1 · Cited by 9
“Patients on hydrocortisone replacement had increased total cholesterol, triglycerides, glycosylated haemoglobin, and waist circumference compared with ACTH-sufficient patients [38].”
BackgroundInfluentialUpdates in growth hormone treatment and mortality
Sherlock, M., & Stewart, P. M. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328363184d · Cited by 9
Bergthorsdottir, R., Espósito, D., Olsson, D. S., Ragnarsson, Ó., Dahlqvist, P. M., Bensing, S., Nåtman, J., Johannsson, G., & Nyberg, F. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13731 · Cited by 9
Self-citationLong-term effects of radiotherapy on cardiovascular risk factors in acromegaly
Ronchi, C. L., Verrua, E., Ferrante, E., Bender, G., Sala, E., Lania, A. G., Faßnacht, M., Beck‐Peccoz, P., Allolio, B., Spada, A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1105 · Cited by 9
Metadata
- Authors
- Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G.
- Affiliations
- Department of Endocrinology (H.F., G.J.), Sahlgrenska Academy at Gothenburg’s University, SE-413 45 Gothenburg, Sweden
- St Bartholomew's Hospital (GB)
- KIGS/KIMS/ACROSTUDY Medical Outcomes (M.K.-H., A.M.), Endocrine Care, Pfizer, SE-191 90 Sollentuna, Sweden
- Pfizer (Sweden) (SE)
- University of Gothenburg (SE)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3954-3961
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2137769079
- Cited by
- 321
- References
- 48
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 25 · 2023: 12 · 2022: 13 · 2021: 17 · 2020: 24 · 2019: 18 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 20 · 2014: 23 · 2013: 12 · 2012: 19
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, glucocorticoid replacement therapy, cortisol, cortisone acetate, prednisolone, dexamethasone, growth hormone replacement therapy, metabolic profile, body mass index, waist circumference, serum lipids, HbA1c, insulin-like growth factor I, diabetes mellitus, stroke, myocardial infarction, comorbidities, glucocorticoid dose
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Aged, Female, Glucocorticoids, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Risk Factors, Growth Hormone, Comorbidity, Body Mass Index, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.